macrophage development, activation and ... - Semantic Scholar

OPEN

Clinical & Translational Immunology (2016) 5, e62; doi:10.1038/cti.2015.46 & 2016 Australasian Society for Immunology Inc. All rights reserved 2050-0068/16 www.nature.com/cti

REVIEW

Histone deacetylases in monocyte/macrophage development, activation and metabolism: refining HDAC targets for inflammatory and infectious diseases Kaustav Das Gupta1,2,3,4, Melanie R Shakespear1,2,3,4, Abishek Iyer1,2,3, David P Fairlie1,2,3 and Matthew J Sweet1,2,3 Macrophages have central roles in danger detection, inflammation and host defense, and consequently, these cells are intimately linked to most disease processes. Major advances in our understanding of the development and function of macrophages have recently come to light. For example, it is now clear that tissue-resident macrophages can be derived from either blood monocytes or through local proliferation of phagocytes that are originally seeded during embryonic development. Metabolic state has also emerged as a major control point for macrophage activation phenotypes. Herein, we review recent literature linking the histone deacetylase (HDAC) family of enzymes to macrophage development and activation, particularly in relation to these recent developments. There has been considerable interest in potential therapeutic applications for small molecule inhibitors of HDACs (HDACi), not only for cancer, but also for inflammatory and infectious diseases. However, the enormous range of molecular and cellular processes that are controlled by different HDAC enzymes presents a potential stumbling block to clinical development. We therefore present examples of how classical HDACs control macrophage functions, roles of specific HDACs in these processes and approaches for selective targeting of drugs, such as HDACi, to macrophages. Development of selective inhibitors of macrophage-expressed HDACs and/or selective delivery of pan HDACi to macrophages may provide avenues for enhancing efficacy of HDACi in therapeutic applications, while limiting unwanted side effects. Clinical & Translational Immunology (2016) 5, e62; doi:10.1038/cti.2015.46; published online 29 January 2016

Macrophages are key innate immune cells occupying specific tissue niches throughout the body. The cells express a plethora of receptor systems that allow them to sense the extracellular environment with exquisite sensitivity and specificity. Such receptors include phagocytic receptors, cytokine receptors, receptors for other host-derived inflammatory mediators and several families of danger-sensing pattern recognition receptors, such as the Toll-like receptors (TLRs) and Nod-like receptors. The combined actions of these detection systems enable macrophages to initiate appropriate inflammatory programs upon perturbation of homeostasis. However, dysregulated and/or chronic inflammation driven by macrophages is central to the pathology of many disease states including autoimmune diseases, cardiovascular diseases, neurodegenerative diseases, inflammatory diseases, infectious diseases and cancer. Through recruitment of inflammatory monocytes and/or local expansion of macrophages at the inflammatory lesion, the host can respond to perturbed homeostasis. Another response mechanism involves changes in macrophage metabolic state, to enable the assignment of available nutrients into distinct metabolic pathways. Indeed, the coordinated control of energy metabolism and cellular activation is 1

essential for innate immune functions.1 Whereas quiescent macrophages primarily use oxidative phosphorylation (OXPHOS) to generate energy in the form of ATP,2 metabolic pathways in TLR-activated macrophages are skewed from mitochondrial respiration toward aerobic glycolysis.3 This switch leads to changes in intracellular levels of metabolites with signaling, antimicrobial and/ or immunomodulatory functions. Hence, there has been considerable interest in defining the precise molecular switches that control metabolic processes in macrophages. Acetyl coenzyme A (acetyl-CoA), which is a central molecule in metabolic pathways,4 also acts as a donor molecule for acetylation of lysine residues on proteins. This process is controlled by histone acetyl transferases and histone deacetylases (HDACs), which regulate the acetylation status of histones and thousands of non-histone proteins. The 18 human HDACs are categorized into either classical HDACs or sirtuins, based on their enzymatic mechanisms of action. Classical HDACs (HDAC1-11) share a conserved deacetylase domain that contains a zinc-binding pocket, whereas non-classical HDACs (the sirtuins) act in an NAD+-dependent manner. Within the classical HDACs, class I HDACs (HDAC1, 2, 3, 8) can assemble

Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland, Australia; 2IMB Centre for Inflammation and Disease Research, The University of Queensland, St Lucia, Queensland, Australia and 3Australian Infectious Diseases Research Centre, The University of Queensland, St Lucia, Queensland, Australia 4These authors contributed equally to this work. Correspondence: A/Professor MJ Sweet, Institute for Molecular Bioscience, The University of Queensland, St Lucia, Qld 4072, Australia. E-mail: [email protected] Received 17 November 2015; revised 22 December 2015; accepted 22 December 2015

HDAC functions in myeloid cells K Das Gupta et al 2

multi-component co-repressor complexes and often act as transcriptional repressors. Nonetheless, they can also promote the expression of specific target genes in some signaling pathways, for example, in type I interferon (IFN) signaling.5 Class II HDACs (HDAC4, 5, 6, 7, 9, 10) have both cytoplasmic and nuclear functions, and the class IIa HDACs (HDAC4, 5, 7, 9) can function by both deacetylase-dependent and -independent mechanisms. Collectively, these properties extend HDAC functions well beyond histone deacetylation. The classical HDACs have essential roles in both the development6 and activation7 of many immune cell types, including macrophages. Moreover, HDAC inhibitors are efficacious in animal models of several inflammation-related diseases.8 Such findings have generated great interest, particularly in relation to the potential development of isoform- or class-specific HDAC inhibitors. Recent reviews have overviewed roles for HDACs in inflammation and immunity.7,9 Given established links between HDACs and macrophages, as well as macrophages and many disease processes, in this review we specifically focus on the involvement of HDACs in regulating macrophage differentiation, activation and metabolism. We also discuss approaches that can be used to selectively target HDACs in macrophages, as these could potentially be harnessed for clinical development. MONOCYTE/MACROPHAGE DIFFERENTIATION AND REGULATION BY HDACs The many faces of macrophage development The vertebrate hematopoietic system is generated by two highly coordinated, successive waves. In the mouse embryo, ‘primitive’ hematopoiesis is a transient early wave occurring from E7 in the yolk sac and giving rise to multi-lineage erythro-myeloid progenitors, which express the Csf-1r.10,11 These cells migrate to the fetal liver before E10.5 and give rise to fetal erythrocytes, monocytes, macrophages and granulocytes. Yolk sac-derived phagocytes have the potential to seed various tissues and to be maintained as resident tissue macrophages throughout adulthood, independently of bone marrow progenitors.11–14 At approximately E10, ‘definitive’ hematopoiesis begins with the emergence of hematopoietic stem cells (HSCs) in the aorta–gonadal–mesonephros region.15 These cells are characterized by their ability to engraft an irradiated recipient and provide a long-term supply of all blood cell populations throughout adult life. Once the circulatory system begins to function at E10.5, they migrate through the circulation to colonize the fetal liver and placenta. The fetal liver operates as the major hematopoietic organ after E11.5. Here, HSC are expanded before their migration to the thymus (E11-12), spleen (E12) and bone marrow (E16 onward) before birth. Adult tissue-resident macrophages are maintained by at least two mechanisms. The traditional view is one of a linear process in which committed bone marrow progenitors gave rise to circulating blood monocytes, which, upon entering tissues, differentiate into mature macrophages. HSC are a multipotent, self-renewing population that give rise to multipotent progenitors, which can further commit to distinct differentiation programs. Common myeloid progenitors have the potential to differentiate into the megakaryocyte/erythroid lineage, as well as into granulocytes, dendritic cells (DCs) and monocytes/ macrophages. In steady-state adult hematopoiesis, production of myeloid cells is tightly controlled by several growth factors including stem cell factor, interleukin-3 (IL-3), granulocyte-macrophage colonystimulating factor, granulocyte colony-stimulating factor, colonystimulating factor 1 and IL-34. CSF-1 is particularly important for monocyte/macrophage development, as mice deficient in this growth Clinical & Translational Immunology

factor or its receptor are severely monocytopenic and several tissueresident macrophage populations are absent or reduced.16 The derivation of resident tissue macrophages from monocytes is unequivocally the case for some populations such as those of the colonic mucosa.17 However, sophisticated fate-mapping experiments have revealed that tissue macrophages can also be seeded from primitive yolk-sac progenitors before birth, and can be maintained as a self-renewing population independent of bone marrow progenitors. This is particularly the case for microglia in the brain.18 However, studies on the contribution of embryonic phagocytes to adult macrophage populations have typically been conducted on young adult mice, and under homeostatic conditions. Under physiological stress, as occurs during infection and/or injury, effector cells are in high demand and must be replenished by emergency myelopoeisis. This is driven by enhanced production of myeloid growth factors such as granulocyte-macrophage colony-stimulating factor and colonystimulating factor 1,19 inducible production of cytokines such as IL-1β and IL-6 that can also direct myelopoiesis, and through direct activation of the HSC themselves.20 In these circumstances, monocytes are a major source of the macrophages within the inflammatory lesion. Even during ageing, tissue-resident macrophages in the heart21 and lung11 are replenished from monocytes, and thus monocytes do indeed make a major contribution to the tissue macrophage population during the lifespan of an animal. Nonetheless, the distinct mechanisms by which tissue macrophage populations can be generated has significant implications for understanding macrophage functions in different microenvironments and disease states. HDACs: pulling the strings of HSC to monocyte to macrophage differentiation Cell fate decisions in the hematopoietic hierarchy are controlled by epigenetic mechanisms. Much of our initial knowledge of HDAC-mediated control of monocyte/macrophage development is derived from clinical trials of HDAC inhibitors as anticancer agents. Pan-HDAC inhibition can cause myelosuppression, particularly thrombocytopenia,22 thus implicating HDACs in monocyte/macrophage development. Studies in non-malignant cells also support the view that HDACs regulate myeloid development. For example, treatment of CD34+ve cord blood cells with the HDAC inhibitor (HDACi) valproic acid (VPA) inhibited erythroid differentiation, but promoted myelo-monocytic differentiation.23 This was correlated with an increase in PU.1 expression. In contrast, treatment of mature macrophages with HDACi markedly decreased PU.1 protein expression,24,25 implying that HDACs may differentially regulate PU.1 in mature macrophages versus precursors. Genetic studies also implicate HDACs in HSC fate decisions and myeloid development.26 Class I HDAC expression was low in CD34+ve human progenitor cells, increased in more differentiated CD34− ve progenitors and erythroid precursors, but was decreased in myeloid cells. Forced overexpression of HDAC1 by reconstitution of HDAC1transduced progenitor cells into irradiated donors resulted in reduced CD11b+ve myeloid cells but normal red blood cell numbers 10 weeks after transplantation, suggesting that HDAC1 function must be downregulated during myelopoiesis.26 Other reports have identified essential roles for HDAC1, HDAC2 and HDAC3 in the maintenance of homeostatic HSC, as well as committed myeloid progenitor cells.27,28 Interestingly, myeloid-specific deletion of HDAC3 did not interfere with the capacity of bone marrow cells to differentiate to macrophages in vitro.29 Combined, these studies suggest that HDAC3 is most likely to control very early cell fate decisions during myeloid differentiation. However, gene silencing of HDAC3 in human cord


blood stem cells expanded CD34+ve immature progenitors without compromising their ability to self-renew and repopulate the hematopoietic compartment.30 In this study, monocyte lineage commitment and maturation of monocyte precursors was not affected, suggesting that HDAC3 controls HSC expansion but not differentiation potential. Whether this relates to differences in experimental systems (for example, knockout versus gene silencing) remains to be determined. As cells progress down the hematopoietic hierarchy and make increasing commitments to specific cell lineages, other HDACs appear to be important in determining cell fates. For example, HDAC7 repressed the differentiation of pre-B cells to myeloid cells in a transdifferentiation model of lymphoid-primed multipotent progenitor to B-cell commitment choice.31 In contrast, HDAC7 is expressed in mature primary mouse macrophages,32 the BV2 mouse microglial cell line33 and human macrophage-like cell lines.34 Collectively, these studies suggest that HDAC7 is transiently downregulated during macrophage differentiation, and then re-expressed to enable it to participate in mature macrophage functions (see ahead). Another classical HDAC implicated in myeloid cell fate decisions is HDAC11. Using transgenic mice expressing green fluorescent protein from the Hdac11 promoter, Sahakian et al.35 observed high reporter gene expression in bone marrow granulocytes and low expression in monocytes. Using global Hdac11 knockout mice, the authors demonstrated that this HDAC negatively regulates myeloid-derived suppressor cell development and function, at least in part through control of suppressive IL-10 production. Induction of emergency myelopoiesis using Freund’s adjuvant in Hdac11 − / − mice resulted in a greater expansion of granulocytes as compared with wild-type mice, although studies with myeloid-specific Hdac11 knockout mice are necessary to determine cell-intrinsic effects of HDAC11 in regulating myeloid development. Collectively, the above literature suggests that class I HDACs have important roles in maintaining the stem cell pool and directing early lineage choices. As commitment progresses down the myeloid lineage, class II and IV HDACs appear to have more specialized roles. Do HDACs contribute to primitive hematopoiesis and the maintenance of tissue macrophage populations under homeostasis? Not surprisingly, little is known about how HDACs contribute to the establishment of resident tissue macrophages from embryonic precursors. Non-mammalian models have recently been used to test how HDAC activity may regulate primitive hematopoiesis. Zebrafish embryos treated with VPA failed to initiate primitive hematopoiesis because of a block in expression of critical hematopoietic transcription factors such as Scl, Lmo2 and Gata2.36 Conversely, ectopic expression of human HDAC1 in these embryos enhanced expression of these hematopoietic markers, suggesting that one or more class I HDACs is required for primitive hematopoiesis. Primitive hematopoiesis in Xenopus occurs in analogous compartments to that of zebrafish; erythropoiesis occurs in posterior ventral blood islands and myelopoiesis in the anterior ventral blood islands. Shah et al.37 demonstrated that either VPA or trichostatin A (TSA) treatment during gastrulation resulted in the absence of erythrocytes, but did not affect the myeloid lineage. The same study also examined isolated yolk-sacs from mouse embryos at E7.5; similar to the findings with Xenopus, VPA caused a dose-dependent loss of erythroid progenitors without affecting overall cell viability. Using more selective inhibitors, the authors also identified class I HDACs as having important roles in the first wave of blood cell development. Collectively, these data suggest that HDACs have more pronounced roles in erythroid development during

primitive hematopoiesis, but more sophisticated mechanistic studies are now required to ascertain whether specific HDACs regulate embryonic macrophage development and whether this impacts on adult tissue-resident macrophage populations. If so, the ontogeny of a given tissue-resident macrophage population may be an important variable in how specific macrophage populations are affected by HDACi. HDACs IN THE CONTROL OF MONOCYTE/MACROPHAGE ACTIVATION HDAC-mediated regulation of innate immune pro-inflammatory signaling pathways Monocytes, inflammatory macrophages and tissue-resident macrophages have an inherent plasticity, enabling them to shape and coordinate inflammatory responses, microbial destruction, tissue repair and wound healing. Indeed, a broad spectrum of macrophage phenotypes can exist, depending on the specific microenvironment and stimuli encountered.38 Pattern recognition receptors lie at the heart of most inflammatory processes, and thus pattern recognition receptor signaling pathways, and macrophages in general, represent tractable targets for inflammation-related diseases. The efficacy of HDACi in numerous animal models of inflammatory diseases has sparked great interest in HDACs as inflammation targets (reviewed in Shakespear et al.7 and Halili et al.8). Specific anti-inflammatory mechanisms of HDACi, as well as how individual HDAC enzymes promote innate immune pro-inflammatory responses, have been identified in recent years (Figure 1). Many such studies have focused on TLR and type I IFN signaling pathways. However, it is clear that HDACi can also have pro-inflammatory effects in certain settings, and that specific HDACs constrain inflammatory signaling (Figure 1). Indeed, it seems that an individual HDAC enzyme can have both proand anti-inflammatory functions in different molecular pathways, thus highlighting some of the challenges associated with selective HDAC targeting. We have previously reviewed this area in detail,7 and below we highlight key concepts and recent developments in this area. Anti-inflammatory effects of HDACi and pro-inflammatory HDAC functions Some of the earlier reports on the anti-inflammatory properties of HDACi highlighted that the broad-spectrum HDACi, suberoylanilide hydroxamic acid (SAHA)39 and ITF2357,40 diminished production of key pro-inflammatory cytokines from lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells. Similar effects were reported in subsequent studies.25,41,42 Several mechanisms appear to contribute to these anti-inflammatory effects. HDACi impaired the recruitment of the RelA subunit of nuclear factor (NF)-κB and IFN regulatory factor-1 to the promoter of the HDAC-dependent IL-12p40 gene in murine DC.42 Another mechanism relates to HDACi-triggered hyperacetylation of mitogen-activated protein kinase phosphatase-1, which leads to inhibition of LPS-induced mitogen-activated protein kinase p38 activation.43 In this case, the class I HDACs, HDAC1, 2 and 3 were linked to deacetylation of mitogen-activated protein kinase phosphatase-1, which enhanced TLR-inducible mitogen-activated protein kinase p38 activation. However, other studies did not observe notable effects on TLR-activated mitogen-activated protein kinase signaling pathways in different cell populations,42,44 suggesting that there may be cell type-specific effects in HDACi-mediated control of mitogen-activated protein kinase phosphatase-1 activation. The anti-inflammatory effects of HDACi have also been linked to their capacity to target the pro-inflammatory transcription factor Clinical & Translational Immunology

HDAC functions in myeloid cells K Das Gupta et al 4 Key Positively regulates Negatively regulates

TLR

p38

MKP-1

Autophagy HDAC i

HDAC

? NFκB

AP-1

HDAC1/2/3

? pro IL-1β

IL-1β

PLZF

HDAC mitoROS

Phagocytosis

NFκB IκB

TLR

NO ROS

HDAC i Pro-Inflammatory genes Cytokines: IL-12p40, IL-6, Tnf-α Chemokines: Ccl-2, Ccl-7 Other mediators: Cox-2, Pai-1, Edn-1

HDAC1

Glycolysis

HDAC5/7

Pentose Phosphate Pathway

HDAC i HDAC11

HDAC3

HDAC i HDAC6

IL-10

IL-4 dependent genes

NuRD

Phagocytic genes

TCA Cycle OXPHOS

Nos2

HDAC i

NADPH oxidase subunits

PRRs

Viral gene expression

Mi-2β Autophagy

Anti-inflammatory genes

HDAC i

Inflammatory Responses

Metabolism

Antimicrobial Response

Figure 1 HDACs in macrophage inflammatory, antimicrobial and metabolic pathways. (a) TLR signaling pathways can be both positively (for example, HIF-1α and MAP kinase phosphatase-1 (MKP-1)) and negatively (for example, NF-κB) regulated by HDACs. (b) HDACs control expression of genes required for phagocytosis, the respiratory burst and NO production. Although the roles of HDACs in TLR-inducible autophagy and mitochondrial ROS (mitoROS) production in macrophages are still emerging, HDACi have been shown to promote autophagy-mediated clearance of HIV-1 from macrophages. (c) Glycolysis and the TCA cycle are intimately linked with macrophage activation status. Correlations between metabolic pathways and macrophage inflammatory and antimicrobial responses are shown. Effects of HDACi are denoted in light green, whereas individual HDACs are shown in blue. Positive regulation is depicted with a green arrow, whereas negative regulation is shown in red.

hypoxia-inducible factor (HIF)-1α.32 A number of classical HDACs can associate with and/or regulate HIF-1α function.7 Moreover, HDAC7, which is expressed at elevated levels in inflammatory macrophages, interacts with HIF-1α and promotes inducible expression of a sub-set of LPS target genes in macrophages.32 Intriguingly, this effect was restricted to HDAC7-u, an alternatively spliced isoform of HDAC7 lacking the first 22 amino acids at the N-terminus. The full-length HDAC7 isoform did not have this effect; this likely relates to the inability of HDAC7-u to bind the transcriptional co-repressor CTBP1, thus licensing this isoform as a transcriptional activator. Like HDAC7, HDAC5 was also shown to promote LPS-inducible inflammatory responses in human and mouse macrophage cell lines,45 although whether this also involves HIF-1α is unknown at this stage. Interestingly, HDAC7 exerts many of its biological effects through an interaction with HDAC3, which can provide enzymatic activity to the complex.46 In this respect, Hdac3− / − macrophages also have impaired inflammatory responses, which was attributed to the loss of IFN-β–STAT signaling.47 An independent study also reported that Hdac3− / − macrophages are polarized toward an alternatively activated phenotype, as evidenced by expression of associated markers such as Clec7a and Arg1.29 HDAC3 binds to the enhancer regions of PU.1 target genes and suppresses IL-4-dependent gene expression. Thus, loss of HDAC3 releases this break and polarizes the macrophages to an alternatively activated phenotype. Finally, another broad mechanism by which HDACi can exert antiClinical & Translational Immunology

inflammatory effects is through upregulating the expression or activity of anti-inflammatory molecules or pathways, as has been reported for the Mi-2/NuRD transcriptional repressor complex.41 This may also be the case for IL-10, as HDAC11 suppresses the LPS-inducible expression of this anti-inflammatory cytokine.48 Pro-inflammatory effects of HDACi and anti-inflammatory HDAC functions Not surprisingly, given the broad effects of HDACi in regulating diverse cellular processes, HDACi can also amplify specific macrophage inflammatory responses. For example, TSA enhanced LPSinducible expression of Cox-225 and Pai-149 in macrophages. Similarly, the HDACi, LAQ824, also amplified certain LPS responses in murine macrophages.50 In terms of mechanisms by which specific HDACs suppress macrophage inflammatory responses, most studies point toward the involvement of class I HDACs. For example, in addition to promoting inflammatory responses in macrophages (above), the class I HDAC, HDAC3, can limit NF-κB-dependent inflammatory gene expression, as part of a complex containing the promyelocytic leukemia zinc-finger protein.51 In addition to HDAC3, HDAC1 acts as a negative regulator of TLR signaling by targeting the promoters of inflammatory genes such as Il-12p40, Cox-2 and Ifnβ (reviewed in Shakespear et al.7), probably acting, at least in part, by associating with the p65 subunit of NF-κB.52 HDACs appear to be particularly important for feedback control of TLR-activated inflammatory responses.25 A recent study identified one specific mechanism


by which this can occur; the ten eleven translocation family member Tet2 is LPS-inducible in macrophages and recruits the class I HDAC, HDAC2, to the Il-6 gene to switch off the expression of this pro-inflammatory cytokine.53 Pro-inflammatory effects of HDACi may also relate to the capacity of some HDACs to promote anti-inflammatory responses. For example, in contrast to HDAC11, HDAC6 acts as a transcriptional activator of IL-10.54 HDAC6 was recruited to the Il-10 promoter, and genetic knockout or knockdown of HDAC6, as well as inhibition of its enzymatic activity, diminished the levels of IL-10 produced by murine macrophages. Finally, as an example of amplification of inflammatory responses independently of classical gene regulation, HDACi amplified LPS-induced secretion of IL-1β in human and murine primary DC and macrophages, without altering the expression of pro-IL-1β.55 In this case, HDACi triggered inflammasome-independent IL-1β cleavage and release. Given the central role of this cytokine in inflammation-associated pathology, this finding again highlights potential contraindications that may arise from the use of pan HDACi. HDAC functions in macrophage-mediated host defense Monocytes and macrophages have several roles in host defense. Through their danger detection systems, they initiate and coordinate inflammatory responses to limit the spread of infection.56 They also act as professional phagocytes, targeting ingested microorganisms for immediate destruction, via reactive oxygen species (ROS) and the degradative environment of the phagolysosome.56 Finally, TLR signaling targets persistent intracellular pathogens by upregulating the expression of genes involved in direct antimicrobial responses. For example, TLR-inducible expression of inducible nitric oxide (NO) synthase, encoded by Nos2, enables mouse macrophages to generate NO as an alternative means of free radical attack against intramacrophage pathogens such as Mycobacterium and Leishmania.57 HDACi have been shown to impair innate immune responses to infection, both in vitro and in vivo, in mouse models,41,58 thus implying that HDACs have essential roles in host defense. Below, we focus on HDAC-mediated control of macrophage antimicrobial responses. Phagocytosis requires the recognition of an external particle by either opsonic or non-opsonic receptors. Transcriptome analysis of TSA-treated murine bone marrow-derived macrophages revealed widespread inhibition of TLR-inducible expression of pattern recognition receptors, scavenger receptors and cytosolic danger-sensing receptors.41 TSA and VPA also downregulated the expression of other integrin receptors that are involved in the ingestion of opsonin-coated particles (for example, Itgax, Itgb2) in mouse bone marrow-derived macrophages.58 Consistent with such effects, pre-treatment of bone marrow-derived macrophages with HDACi impaired phagocytoic uptake of Escherichia coli and Staphylococcus aureus. Furthermore, in in vivo infection models in mice, HDACi increased susceptibility to Klebsiella pneumoniae and Candida albicans. Engagement of phagocytic receptors is intimately linked to the assembly of the NADPH oxidase system and the immediate generation of ROS upon particle uptake, a process known as the respiratory burst. Pre-treatment of bone marrow-derived macrophages with HDACi also disrupted the respiratory burst; total cellular ROS production was inhibited upon microbial challenge or triggering with phorbol myristate acetate.58 This was consistent with HDACi-mediated downregulation of expression of many of the genes encoding NADPH oxidase subunits. Several of these are also upregulated by IFN-γ, thus enabling this pro-inflammatory cytokine to prime the respiratory burst in macrophages. Treatment of DC with the HDACi, LAQ824, led to a selective defect in IFN-γ

production from Th1 cells,59 providing an additional mechanism by which HDACi may compromise NADPH oxidase-dependent ROS production by macrophages. TLR-inducible antimicrobial responses in macrophages include NO generation, autophagy and mitochondrial ROS production. Treatment of murine macrophages with the HDACi TSA, MS-275 or SAHA was reported to disrupt inducible NO production,43,60 and HDAC1/2/3 silencing had similar effects.43 Similarly, the HDACi KBHA42 inhibited LPS-induced Nos2 mRNA and NO production in RAW264.7 macrophage-like cells and peritoneal macrophages.61 However, HDACi did not affect NF-κB binding to response elements in the Nos2 promoter, implicating alternative mechanisms. Instead, HDACi treatment increased recruitment of a transcriptional repressor complex, containing cyclin-dependent kinase-8, cyclin C and the mediator complex-12 and -13, at the promoter of Nos2 gene,60 providing one potential mechanism. Apart from an NF-κB-binding site, the Nos2 gene promoter harbors Oct1 and Oct2 response elements, and TSA pre-treatment also reduced LPS-inducible Oct2 expression in RAW264.7 cells.62 It should also be noted that some apparent inconsistencies exist in the literature regarding HDACregulated Nos2 expression. For example, one study reported that, unlike TSA, other HDACi (SAHA, VPA and sodium butyrate) did not affect the production of NO from RAW264.7 cells or primary murine macrophages.63 Moreover, the HDACi TSA, SAHA and M344 were reported to amplify LPS-induced NO levels in microglial cells in a dose-dependent manner.64 It is possible that these discrepancies may relate to differences in the phenotypes of the macrophage populations being studied and/or concentrations of HDACi being used. Despite the interest in the roles of TLR-inducible autophagy and mitochondrial ROS generation in pathogen elimination, as yet, little is known of how HDACs regulate these two antimicrobial programs in macrophages. Studies in other cellular systems would suggest that this is likely to be the case,65,66 and indeed, HDACi reduced human immunodeficiency virus-1 (HIV-1) release from macrophages by promoting autophagosomal degradation.67 Further investigations of HDAC-mediated control of autophagy and mitochondrial ROS production in macrophages are thus clearly warranted. In contrast to findings from mouse studies, a limited number of studies suggest that HDACi may actually boost human macrophage antimicrobial responses. This is perhaps not so surprising, given some known differences in human and mouse innate immunity.68 The HDACi MS-275 and butyric acid restored HLA-DR gene expression in Mycobacterium-infected human macrophage-like THP-1 cells,69 which would be predicted to have host-protective effects. Another study showed that pharmacological or genetic silencing of HDAC1 decreased intracellular bacterial loads of the Rickettsial pathogen Anaplasma phagocytophilum in infected THP-1 cells.70 In that report, HDAC1 bound to promoter regions of various host defense genes, presumably repressing their expression. Such studies hint that some pathogens may manipulate host HDAC machinery as part of their subversion strategies. In keeping with this view, HIV latency has also been linked to repression of HIV long terminal repeat promoter activity by class I HDACs,71 a phenomenon that could potentially be exploited by reactivating viral reservoirs for CD8+ve T-cell-mediated clearance. Despite the clinical interest in HDACi in this particular context, there still remains surprisingly little known about HDAC-mediated control of human macrophage antimicrobial pathways, however, this will undoubtedly be an area of intense future investigation. Clinical & Translational Immunology


MYELOID HDACs IN IMMUNOMETABOLISM Immunometabolism in macrophage polarization and effector functions Under homeostatic conditions, most cells utilize the cytosolic glycolysis machinery to convert glucose to pyruvate, which is then transported to the mitochondria to enter the tricarboxylic acid cycle (TCA) as acetyl-CoA.4 Acetyl-CoA is then consumed by the energyefficient, but relatively slow, process of OXPHOS to generate ATP.4,72 When under stress, however, macrophages reprogram their metabolism to accumulate key carbon metabolites that have important signaling roles and/or contribute to direct antimicrobial functions.72,73 Below, we provide examples of macrophage metabolic adaptations and speculate on their likely links with macrophage-expressed HDACs. The ability of myeloid cells to divide, differentiate and carry out effector functions in response to sterile and infectious stimuli requires changes in their metabolic state to enable available nutrients to be directed into distinct cellular metabolic pathways such as glycolysis, the pentose phosphate pathway (PPP) and the TCA cycle.72,73 Resting macrophages generally utilize the TCA cycle to generate ATP via OXPHOS.72 However, the balance between OXPHOS and glycolysis is shifted in TLR-activated macrophages, with a decrease in OXPHOS and an increase in glycolysis that is accompanied by enhanced pyruvate to lactate conversion.72,74 The PPP, which is critical for NADPH-dependent ROS production, is also highly active in classically activated macrophages.72,74 On the other hand, alternatively activated macrophages display reduced lactate production and secretion, instead utilizing fatty acid oxidation, an intact TCA cycle and OXPHOS as hallmark metabolic features.72 Recent metabolic profiling of macrophages in different activation states has shed insights into mechanisms responsible for such effects. For example, in IFN-γ +LPS-activated macrophages, the TCA cycle is interrupted at the point of conversion of isocitrate to α-ketoglutarate, probably because of rapid downregulation of isocitrate dehydrogenase 1 that catalyzes this reaction.75 Similarly, another study showed that LPS-mediated downregulation of carbohydrate kinase-like protein in macrophages was required for metabolic reprogramming and for optimal proinflammatory signaling and cytokine responses.74 Such findings suggest that targeting specific metabolic pathways may enable manipulation of macrophage activation and effector functions. Indeed, inhibiting glycolysis attenuated LPS-inducible pro-IL-1β expression in LPS-activated macrophages.3 Interestingly, some of the metabolites that accumulate in activated macrophages can contribute to macrophage effector functions by acting as direct antimicrobial agents (for example, itaconic acid) and/or signaling molecules. In the case of the latter, the TCA cycle intermediate succinate has been linked to stabilization of HIF-1α and sustained pro-IL1β expression.3 Although key enzymes and metabolites that control both macrophage metabolism and functional status are beginning to be elucidated, there is much still to learn about the upstream signaling processes. Given their dual roles in regulating metabolism and immune functions,76 HDACs represent prime candidates. HDACs in immunometabolism Lysine acetylation by histone acetyl transferases involves the transfer of an acetyl group from acetyl-CoA to the target lysine residue of a protein, whereas HDACs catalyze the reverse reaction.77 It thus follows that histone acetyl transferases and HDACs can regulate cellular availability of acetyl-CoA,76,77 a central intermediate within multiple metabolic pathways including glycolysis, OXPHOS and β-oxidation of fatty acids.4 It is also clear that lysine acetylation regulates the activity and functions of many enzymes in intermediary metabolic pathways, Clinical & Translational Immunology

including glycolysis and the TCA cycle (Figure 2),78,79 for example, by regulating enzymatic activity and/or protein stability.77 These observations suggest a complex regulatory loop in which intracellular concentrations of acetyl-CoA control global lysine acetylation patterns, which can in turn fine tune metabolic pathways to provide metabolic flexibility to the cell during stress.4,76 Thus, histone acetyl transferases and HDACs are poised to act as molecular links between cellular metabolism, inflammation and infection. The NAD-dependent sirtuins (class III HDACs) are thought to have particularly important roles in controlling acetylation status of various metabolic enzymes,80 however, classical HDACs are also likely relevant.77,81 For example, TSA, a pan-inhibitor of classical HDACs, enhanced both glycolysis and OXPHOS in IFN-γ+LPS-activated macrophages,82 thus implicating this class of HDAC in regulating macrophage metabolic status. The surprising fact that HDACi boosted activities of both of these metabolic pathways in activated macrophages suggests that classical HDACs may regulate both cytoplasmic and mitochondrial metabolic enzymes. Further evidence of the interplay between HDACs and metabolic pathways in macrophages comes from the observation that LPS promotes the degradation of HDAC4 in macrophages, and this process requires active glycolysis.33 Detailed acetylome analyses have not yet been reported in myeloid cells, and little is known about how acetylation status of metabolic enzymes affects macrophage metabolism, phenotypes and effector functions. Nonetheless, studies in other cellular systems suggest that this is very likely to be the case. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) catalyzes the conversion of glyceraldehyde-3-phosphate to 1,3 bisphosphoglycerate (step 6) in the glycolysis pathway. In mammalian cells, glucoseinduced acetylation of GAPDH at K254 enhanced its enzymatic activity, whereas glucose deprivation promoted an interaction with HDAC5, its deacetylation and a reduction in activity.83 Thus, deacetylation of GAPDH by classical HDACs would be predicted to limit glycolysis in macrophages, perhaps leading to a corresponding reduction in inflammatory responses. Interestingly, like many metabolic enzymes, GAPDH also has ‘moonlighting functions’; for example, it can translocate to the nucleus to regulate gene expression. Under apoptotic stress, acetylation of residues K117, 227 and 251 is required for the nuclear translocation of GAPDH.84 Thus, GAPDH acetylation may be an important switch controlling metabolic and gene regulatory functions. Another enzyme in the glycolysis pathway, phosphoglycerate mutase 1, catalyzes the interconversion of 3-phosphoglycerate to 2-phosphoglycerate (step 8). Acetylation of lysine residues K251, K253 and K254 changes the confirmation of this enzyme, enhancing its activity.77 Glucose deprivation results in deacetylation of phosphoglycerate mutase 1, reducing its activity and causing a switch from glycolysis to fatty acid oxidation.85 As glucose uptake and glycolysis is enhanced in activated macrophages, deacetylation of phosphoglycerate mutase 1 may provide an additional regulatory mechanism to control glycolysis and the inflammatory status of macrophages. Parallel to glycolysis, the PPP has a specialized role in innate immune cells in generating reducing power for the respiratory burst, and there is some evidence that classical HDACs regulate key enzymes in this pathway. For example, in cancer cells, HDAC4 deacetylates 6-phosphogluconate dehydrogenase at residues K76 and K294, resulting in decreased enzymatic activity and inhibition of glucose metabolism via the PPP shunt.86 Thus, deacetylation of 6-phosphogluconate dehydrogenase by classical HDACs in macrophages may provide a regulatory mechanism constraining the PPP and macrophage antimicrobial responses. As one example of acetylation-

HDAC functions in myeloid cells K Das Gupta et al 7 Glucose Hexokinase

Acetylation regulates:

G6PD

PGI

Fructose-6-phosphate PFK1

Glycolysis

Fructose-1,6-bisphosphate Aldolase TPI

Dihydroxyacetone phosphate

Glyceraldehyde-3-phosphate GAPDH

1,3-Bisphosphoglycerate

6-Phosphogluconate

Positively Pentose Phosphate Pathway

6-Phosphoglucono lactone

Glucose-6-phosphate

Negatively

PGK

3-Phosphoglycerate PGAM

6PGD

2-Phosphoglycerate

NADPH

Enolase

Activation and Effector Functions

Phosphoenolpyruvate

NADPH Oxidase

Reactive Oxygen Species

Ribulose-5-phosphate

PKM

Pyruvate

PEPCK

Host Defense

PDH

Ac-CoA

PC

HATs HDACs

CoA

CS

Citrate

Oxaloacetate

ACC

MDH

Malate

TCA Cycle

FH

Isocitrate IDH

NADH/FADH2

Oxidative Phosphorylation

-Ketoglutarate

Fumarate SDH

-KGDH

Succinyl CoA

Succinate

Tissue Repair Wound Healing

SCS

Figure 2 Lysine acetylation is a key control point in intermediate metabolism. Enzymes in glycolysis, the TCA cycle and the PPP for which there is evidence of acetylation are indicated in blue. Enzymes for which there is evidence of deacetylation by classical HDACs (on the basis of pharmacological inhibitors and/ or functional studies with individual HDACs) are boxed, although many of these enzymes can also be deacetylated by sirtuins. Where there is clear evidence for enzyme acetylation affecting protein function in a specific way, this is indicated (green arrows: positive regulation; red arrows: negative regulation). However, in some cases, acetylation can have multiple effects on the functions of a specific metabolic enzyme.

dependent control of the TCA cycle, enzymatic activity of malate dehydrogenase, which catalyzes the conversion of malate into oxaloacetate,78 is enhanced by acetylation at residues K185, 301, 307 and 314.78 Both glucose and the pan-HDAC inhibitor TSA acetylated malate dehydrogenase to increase its activity in human liver cells.78 Thus, HDAC-mediated deacetylation of malate dehydrogenase would be predicted to impair the TCA cycle. It seems unlikely that this relates to fragmentation of the TCA cycle in LPS-activated macrophages as this has been specifically linked to impaired isocitrate dehydrogenase 1 activity,75 but it remains possible that deacetylation-mediated inhibition of malate dehydrogenase provides a means of fine tuning the TCA cycle in macrophages responding to other stimuli. Moreover, given that virtually all of the TCA cycle enzymes can be acetylated (Figure 2),78 acetylation-dependent control of OXPHOS is likely to be operational in macrophages. This conclusion is supported by the observation that pan-HDAC inhibition enhanced OXPHOS activity in activated macrophages.82 Further studies on the roles of specific classical HDACs in regulating metabolic pathways in macrophages are now needed to generate new insights into the control of inflammatory and antimicrobial responses in these cells. MANIPULATING MACROPHAGE FUNCTIONS FOR THERAPEUTIC BENEFIT WITH HDACi HDACi such as Vorinostat/SAHA have been used clinically as chemotherapeutic agents because of their ability to arrest cell cycle, induce apoptosis, promote cell differentiation and shape antitumor

immune responses.87 Despite their clinical use, pan HDACi have also been linked to a number of adverse effects. These include gastrointestinal pathophysiologies (nausea, vomiting and anorexia), hematologic (thrombocytopenia and anemia) and metabolic (liver toxicities) complications,88 as well as increased expression of drug efflux systems,9 and pathways that can promote tumor survival and/or immune escape mechanisms,9 all of which may compromise their effectiveness and/or utility. On the basis of some clinical studies,88 it has been proposed that chemotherapy with HDAC inhibitors may increase susceptibility to infectious diseases. However, such reports can be difficult to interpret, given the immunocompromised state of latestage cancer patients. Moreover, treatment of systemic-onset juvenile idiopathic arthritis patients with the HDAC inhibitor givinostat for 12 weeks was not associated with increased risk of infection.89 Nonetheless, there are clearly concerns about potential long-term side effects of HDACi therapeutic regimes. For example, a clinical trial assessing the efficacy of vorinostat in reactivating HIV transcription in patients on suppressive antiretroviral therapy noted profound effects on gene expression at day 84 of the trial, which was 70 days postcessation of vorinostat treatment.90 Interestingly, gene expression changes at this long time point were apparent in T cells, but were most pronounced in monocytes and DC. Such effects could potentially contribute to variable efficacy of HDACi in reactivating HIV transcription,91 but also highlight concerns about enduring effects of HDACi that may be maintained long after treatment for a particular condition has been completed. These various issues relating to pan Clinical & Translational Immunology


HDACi have driven the pursuit of selective HDACi for antiinflammatory applications, and there has also been some interest in the possibility of selectively targeting pan HDACi to macrophages. HDAC-selective inhibitor development poses a number of significant challenges. Bantscheff et al.92 showed that the inhibitory effects of various HDAC inhibitors depend upon the state of the HDAC in question. For instance, the HDACi, BML-210 inhibited recombinant HDAC1, HDAC2 and HDAC3, but failed to inhibit the HDAC-Sin3A complex, which contains HDAC1 and HDAC2. In contrast, the NCoR-HDAC3 complex was effectively inhibited at low micromolar concentrations. Thus, it is not at all clear that inhibition of individual HDACs in enzyme assays will translate to inhibition of the same HDACs in cells. Generally, it is considered that class IIa HDACs are catalytically inactive, and that they can only deacetylate target proteins by virtue of their association with HDAC3.93 However, this assumption is typically based on enzyme assays using acetylated peptides derived from histone proteins as HDAC substrates, and it is now clear that class IIa HDAC enzymes are active enzymes.94 Furthermore, class IIa HDACs can function as acetyl-lysine binding proteins, and thus class IIa HDACi also have the potential to antagonize this function. The development of class IIa-selective HDACi has generally lagged by comparison with class I- and class IIb-selective HDACi, although some have been reported.95 Interestingly, this study showed that class IIa HDACi have more pronounced effects on myeloid gene expression and functions by comparison with other cell types such as lymphocytes. Thus, class IIa HDAC-selective inhibitors may have applications for manipulating macrophage functions, though the literature reviewed above demonstrates that several other HDACs likely represent viable macrophage targets in different contexts. Even compounds with high specificity for a particular protein target can have undesirable side effects that stem from that target having different functions in different cell types. This is of particular concern for targeting HDACs, as many members of this family are widely expressed across different cell types. Thus, even a highly selective inhibitor against a single HDAC enzyme may trigger unwanted biological effects. An attractive approach that could potentially address this roadblock is to target small molecules selectively to macrophages. The unique phagocytic capacity of macrophages provides one avenue toward this goal.96 Others include use of macrophage-expressed receptors such as folate receptors for drug uptake and delivery,97,98 and the use of pro-drugs that can be hydrolyzed by macrophageexpressed enzymes to concentrate active drug within these cells. With respect to the latter strategy, the serine hydrolase, carboxyesterase-1 is highly enriched in human macrophages and hepatocytes, and a previous study showed that a specific pro-drug could be cleaved to release the broad-spectrum HDACi SAHA within the macrophage cytosol, resulting in greatly enhanced activity in these cells, by comparison with other cell types.99 Moreover, the same report showed that a macrophage-targeted HDACi had increased efficacy, by comparison with the parent compound, in a mouse arthritis model. More recently, clinical trials in cancer have been instigated using a compound derived from this original study.100 Given the interest in potential clinical applications of HDACi in clearing latent HIV reservoirs, the recent demonstration that HDACi also promote viral clearance from macrophages67 is likely to generate further interest in such approaches. Moreover, this finding may also be applicable to other intramacrophage pathogens. Macrophage-targeted HDACi may also offer another advantage in avoiding potential complications associated with reactivation of latent viral infections in other cell types. In a pilot study investigating the safety and efficacy of the HDACi romidepsin for patients with extranodal natural killer/T-cell Clinical & Translational Immunology

lymphoma, reactivation of Epstein–Barr virus was reported.101 Viral reactivation in these patients was associated with fever and liver damage. Others have also noted associations between HDACi therapy and reactivation of latent DNA viruses.102 Macrophage-targeted HDACi would be predicted to be less likely to reactivate pools of latent DNA viruses, which could be particularly advantageous when contemplating therapeutic approaches for immune-compromised patients. Beyond infectious diseases, there is clearly great interest in HDACs as inflammation targets. HDACs that modulate metabolic pathways may be of particular interest here, and one can envisage that, in the future, it may be possible to selectively deliver class I, class IIa and/or class IIb HDAC-selective inhibitors to macrophages to more specifically manipulate metabolic pathways and inflammatory responses in this cell type. CONCLUSIONS The plethora of biological pathways regulated by HDACs in macrophages provides both opportunities and challenges. Based on their roles in myeloid development, macrophage inflammatory pathways, macrophage antimicrobial responses and/or macrophage metabolism, one could probably mount a case for targeting any single macrophageexpressed classical HDAC in the context of inflammation-associated diseases and/or infectious diseases. As one example, the HDAC6 inhibitor tubastatin A reduced levels of pro-inflammatory mediators and also promoted bacterial clearance, and thus survival, in a murine cecal ligation puncture models of sepsis.103 A pharmacological agent with the capacity to simultaneously suppress pathological inflammatory responses and boost host defense pathways may be considered as the holy grail of drug discovery in innate immunity research. However, this is tempered by the fact that even specific HDACi, including HDAC6 inhibitors, are likely to have many unwanted side effects. Tools that enable HDACi to be specifically delivered to macrophages may help to overcome such concerns, particularly in the context of isozyme-specific HDACi. As we further unravel the links between individual HDACs and metabolic, inflammatory and antimicrobial pathways in macrophages, new opportunities for therapeutic applications of HDACi in these contexts are likely to emerge in the future. CONFLICT OF INTEREST The authors declare no conflict of interest.

ACKNOWLEDGEMENTS This work was supported by a National Health and Medical Research Council of Australia (NHMRC) project grant (APP1047921) to MJS, DPF and AI. MJS and DPF are supported by an NHMRC Senior Research Fellowship (APP1107914) and an NHMRC Senior Principal Research Fellowship (APP1027369), respectively.

1 2

3

4 5

6

McGettrick AF, O'Neill LAJ. How metabolism generates signals during Innate Immunity and Inflammation. J Biol Chem 2013; 288: 22893–22898. Rodriguez-Prados JC, Traves PG, Cuenca J, Rico D, Aragones J, Martin-Sanz P et al. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J Immunol 2010; 185: 605–614. Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 2013; 496: 238–242. Pietrocola F, Galluzzi L, Bravo-San Pedro JM, Madeo F, Kroemer G. Acetyl coenzyme A: a central metabolite and second messenger. Cell Metab 2015; 21: 805–821. Xu D, Holko M, Sadler AJ, Scott B, Higashiyama S, Berkofsky-Fessler W et al. Promyelocytic leukemia zinc finger protein regulates interferon-mediated innate immunity. Immunity 2009; 30: 802–816. Fairlie DP, Sweet MJ. HDACs and their inhibitors in immunology: teaching anticancer drugs new tricks. Immunol Cell Biol 2012; 90: 3–5.

HDAC functions in myeloid cells K Das Gupta et al 9 7 8 9

10

11

12

13

14

15

16

17

18

19 20

21

22

23

24 25

26

27

28

29

30

31

32

33

34

Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 2011; 32: 335–343. Halili MA, Andrews MR, Sweet MJ, Fairlie DP. Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 2009; 9: 309–319. Falkenberg KJ, Johnstone RW. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 2014; 13: 673–691. McGrath KE, Frame JM, Fegan KH, Bowen JR, Conway SJ, Catherman SC et al. Distinct sources of hematopoietic progenitors emerge before HSCs and provide functional blood cells in the mammalian embryo. Cell Rep 2015; 11: 1892–1904. Gomez Perdiguero E, Klapproth K, Schulz C, Busch K, Azzoni E, Crozet L et al. Tissueresident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 2015; 518: 547–551. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K et al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science 2012; 336: 86–90. Kierdorf K, Erny D, Goldmann T, Sander V, Schulz C, Perdiguero EG et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci 2013; 16: 273–280. Hoeffel G, Wang Y, Greter M, See P, Teo P, Malleret B et al. Adult Langerhans cells derive predominantly from embryonic fetal liver monocytes with a minor contribution of yolk sac-derived macrophages. J Exp Med 2012; 209: 1167–1181. de Bruijn MF, Speck NA, Peeters MC, Dzierzak E. Definitive hematopoietic stem cells first develop within the major arterial regions of the mouse embryo. EMBO J 2000; 19: 2465–2474. Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 2002; 99: 111–120. Bain CC, Bravo-Blas A, Scott CL, Gomez Perdiguero E, Geissmann F, Henri S et al. Constant replenishment from circulating monocytes maintains the macrophage pool in the intestine of adult mice. Nat Immunol 2014; 15: 929–937. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010; 330: 841–845. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8: 533–544. Nagai Y, Garrett KP, Ohta S, Bahrun U, Kouro T, Akira S et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 2006; 24: 801–812. Molawi K, Wolf Y, Kandalla PK, Favret J, Hagemeyer N, Frenzel K et al. Progressive replacement of embryo-derived cardiac macrophages with age. J Exp Med 2014; 211: 2151–2158. Bishton M, Harrison S, Martin B, McLaughlin N, James C, Josefsson E et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor–induced thrombocytopenia. Blood 2011; 117: 3658–3668. Chateauvieux S, Eifes S, Morceau F, Grigorakaki C, Schnekenburger M, Henry E et al. Valproic acid perturbs hematopoietic homeostasis by inhibition of erythroid differentiation and activation of the myelo-monocytic pathway. Biochem Pharmacol 2011; 81: 498–509. Laribee RN, Klemsz MJ. Loss of PU.1 expression following inhibition of histone deacetylases. J Immunol 2001; 167: 5160–5166. Aung HT, Schroder K, Himes SR, Brion K, van Zuylen W, Trieu A et al. LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. FASEB J 2006; 20: 1315–1327. Wada T, Kikuchi J, Nishimura N, Shimizu R, Kitamura T, Furukawa Y. Expression levels of histone deacetylases determine the cell fate of hematopoietic progenitors. J Biol Chem 2009; 284: 30673–30683. Heideman MR, Lancini C, Proost N, Yanover E, Jacobs H, Dannenberg JH. Sin3a-associated Hdac1 and Hdac2 are essential for hematopoietic stem cell homeostasis and contribute differentially to hematopoiesis. Haematologica 2014; 99: 1292–1303. Summers AR, Fischer MA, Stengel KR, Zhao Y, Kaiser JF, Wells CE et al. HDAC3 is essential for DNA replication in hematopoietic progenitor cells. J Clin Invest 2013; 123: 3112–3123. Mullican SE, Gaddis CA, Alenghat T, Nair MG, Giacomin PR, Everett LJ et al. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev 2011; 25: 2480–2488. Elizalde C, Fernandez-Rueda J, Salcedo JM, Dorronsoro A, Ferrin I, Jakobsson E et al. Histone deacetylase 3 modulates the expansion of human hematopoietic stem cells. Stem Cells Dev 2012; 21: 2581–2591. Barneda-Zahonero B, Roman-Gonzalez L, Collazo O, Rafati H, Islam AB, Bussmann LH et al. HDAC7 is a repressor of myeloid genes whose downregulation is required for transdifferentiation of pre-B cells into macrophages. PLoS Genet 2013; 9: e1003503. Shakespear MR, Hohenhaus DM, Kelly GM, Kamal NA, Gupta P, Labzin LI et al. Histone deacetylase 7 promotes Toll-like receptor 4-dependent proinflammatory gene expression in macrophages. J Biol Chem 2013; 288: 25362–25374. Wang B, Liu TY, Lai CH, Rao YH, Choi MC, Chi JT et al. Glycolysis-dependent histone deacetylase 4 degradation regulates inflammatory cytokine production. Mol Biol Cell 2014; 25: 3300–3307. Aude-Garcia C, Collin-Faure V, Bausinger H, Hanau D, Rabilloud T, Lemercier C. Dual roles for MEF2A and MEF2D during human macrophage terminal differentiation and c-Jun expression. Biochem J 2010; 430: 237–244.

35 Sahakian E, Powers JJ, Chen J, Deng SL, Cheng F, Distler A et al. Histone deacetylase 11: a novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Mol Immunol 2015; 63: 579–585. 36 Li X, Jia S, Wang S, Wang Y, Meng A. Mta3-NuRD complex is a master regulator for initiation of primitive hematopoiesis in vertebrate embryos. Blood 2009; 114: 5464–5472. 37 Shah RR, Koniski A, Shinde M, Blythe SA, Fass DM, Haggarty SJ et al. Regulation of primitive hematopoiesis by class I histone deacetylases. Dev Dyn 2013; 242: 108–121. 38 Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I et al. Transcriptomebased network analysis reveals a spectrum model of human macrophage activation. Immunity 2014; 40: 274–288. 39 Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci USA 2002; 99: 2995–3000. 40 Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005; 11: 1–15. 41 Roger T, Lugrin J, Le Roy D, Goy G, Mombelli M, Koessler T et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011; 117: 1205–1217. 42 Bode KA, Schroder K, Hume DA, Ravasi T, Heeg K, Sweet MJ et al. Histone deacetylase inhibitors decrease Toll-like receptor-mediated activation of proinflammatory gene expression by impairing transcription factor recruitment. Immunology 2007; 122: 596–606. 43 Jeong Y, Du R, Zhu X, Yin S, Wang J, Cui H et al. Histone deacetylase isoforms regulate innate immune responses by deacetylating mitogen-activated protein kinase phosphatase-1. J Leukoc Biol 2014; 95: 651–659. 44 Grabiec AM, Korchynskyi O, Tak PP, Reedquist KA. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis 2012; 71: 424–431. 45 Poralla L, Stroh T, Erben U, Sittig M, Liebig S, Siegmund B et al. Histone deacetylase 5 regulates the inflammatory response of macrophages. J Cell Mol Med 2015; 19: 2162–2171. 46 Fischle W, Dequiedt F, Fillion M, Hendzel MJ, Voelter W, Verdin E. Human HDAC7 histone deacetylase activity is associated with HDAC3 in vivo. J Biol Chem 2001; 276: 35826–35835. 47 Chen X, Barozzi I, Termanini A, Prosperini E, Recchiuti A, Dalli J et al. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc Natl Acad Sci USA 2012; 109: E2865–E2874. 48 Villagra A, Cheng F, Wang HW, Suarez I, Glozak M, Maurin M et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol 2009; 10: 92–100. 49 Halili MA, Andrews MR, Labzin LI, Schroder K, Matthias G, Cao C et al. Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol 2010; 87: 1103–1114. 50 Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J et al. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. J Immunol 2011; 186: 3986–3996. 51 Sadler AJ, Rossello FJ, Yu L, Deane JA, Yuan X, Wang D et al. BTB-ZF transcriptional regulator PLZF modifies chromatin to restrain inflammatory signaling programs. Proc Natl Acad Sci USA 2015; 112: 1535–1540. 52 Aarenstrup L, Flindt EN, Otkjaer K, Kirkegaard M, Andersen JS, Kristiansen K. HDAC activity is required for p65/RelA-dependent repression of PPARdelta-mediated transactivation in human keratinocytes. J Invest Dermatol 2008; 128: 1095–1106. 53 Zhang Q, Zhao K, Shen Q, Han Y, Gu Y, Li X et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 2015; 525: 389–393. 54 Cheng F, Lienlaf M, Perez-Villarroel P, Wang HW, Lee C, Woan K et al. Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Mol Immunol 2014; 60: 44–53. 55 Stammler D, Eigenbrod T, Menz S, Frick JS, Sweet MJ, Shakespear MR et al. Inhibition of histone deacetylases permits lipopolysaccharide-mediated secretion of bioactive IL-1beta via a caspase-1-independent mechanism. J Immunol 2015; 95: 5421–5431. 56 Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011; 11: 723–737. 57 Das P, Lahiri A, Lahiri A, Chakravortty D. Modulation of the arginase pathway in the context of microbial pathogenesis: a metabolic enzyme moonlighting as an immune modulator. PLoS Pathog 2010; 6: e1000899. 58 Mombelli M, Lugrin J, Rubino I, Chanson AL, Giddey M, Calandra T et al. Histone deacetylase inhibitors impair antibacterial defenses of macrophages. J Infect Dis 2011; 204: 1367–1374. 59 Brogdon J, Xu Y, Szabo S, An S, Buxton F, Cohen D et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007; 109: 1123–1130. 60 Serrat N, Sebastian C, Pereira-Lopes S, Valverde-Estrella L, Lloberas J, Celada A. The response of secondary genes to lipopolysaccharides in macrophages depends on histone deacetylase and phosphorylation of C/EBPbeta. J Immunol 2014; 192: 418–426.

Clinical & Translational Immunology

HDAC functions in myeloid cells K Das Gupta et al 10 61 Choi Y, Park SK, Kim HM, Kang JS, Yoon YD, Han SB et al. Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model. Exp Mol Med 2008; 40: 574–581. 62 Lu S, Wu H, Lin Y, Chang S. The essential role of Oct-2 in LPS-induced expression of iNOS in RAW 264.7 macrophages and its regulation by trichostatin A. Am J Physiol Cell Physiol 2009; 296: C1133–C1139. 63 Han SB, Lee JK. Anti-inflammatory effect of trichostatin-A on murine bone marrowderived macrophages. Arch Pharm Res 2009; 32: 613–624. 64 Suuronen T, Huuskonen J, Pihlaja R, Kyrylenko S, Salminen A. Regulation of microglial inflammatory response by histone deacetylase inhibitors. J Neurochem 2003; 87: 407–416. 65 Sun S, Han Y, Liu J, Fang Y, Tian Y, Zhou J et al. Trichostatin A targets the mitochondrial respiratory chain, increasing mitochondrial reactive oxygen species production to trigger apoptosis in human breast cancer cells. PLoS ONE 2014; 9: e91610. 66 True O, Matthias P. Interplay between histone deacetylases and autophagy–from cancer therapy to neurodegeneration. Immunol Cell Biol 2012; 90: 78–84. 67 Campbell GR, Bruckman RS, Chu YL, Spector SA. Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1. J Biol Chem 2015; 290: 5028–5040. 68 Schroder K, Irvine K, Taylor M, Bokil N, Le Cao K, Masterman K et al. Conservation and divergence in Toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages. Proc Natl Acad Sci USA 2012; 109: E944–E953. 69 Wang Y, Curry HM, Zwilling BS, Lafuse WP. Mycobacteria inhibition of IFN- induced HLA-DR gene expression by up-regulating histone deacetylation at the promoter region in human THP-1 monocytic cells. J Immunol 2005; 174: 5687–5694. 70 Garcia-Garcia J, Barat N, Trembley S, Dumler J. Epigenetic silencing of host cell defense genes enhances intracellular survival of the rickettsial pathogen Anaplasma phagocytophilum. PLoS Pathog 2009; 5: e1000488. 71 Shirakawa K, Chavez L, Hakre S, Calvanese V, Verdin E. Reactivation of latent HIV by histone deacetylase inhibitors. Trends Microbiol 2013; 21: 277–285. 72 Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res 2015; 25: 771–784. 73 Norata GD, Caligiuri G, Chavakis T, Matarese G, Netea MG, Nicoletti A et al. The cellular and molecular basis of translational immunometabolism. Immunity 2015; 43: 421–434. 74 Haschemi A, Kosma P, Gille L, Evans CR, Burant CF, Starkl P et al. The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metab 2012; 15: 813–826. 75 Jha AK, Huang SC, Sergushichev A, Lampropoulou V, Ivanova Y, Loginicheva E et al. Network integration of parallel metabolic and transcriptional data reveals metabolic modules that regulate macrophage polarization. Immunity 2015; 42: 419–430. 76 Iyer A, Fairlie DP, Brown L. Lysine acetylation in obesity, diabetes and metabolic disease. Immunol Cell Biol 2012; 90: 39–46. 77 Choudhary C, Weinert BT, Nishida Y, Verdin E, Mann M. The growing landscape of lysine acetylation links metabolism and cell signalling. Nat Rev Mol Cell Biol 2014; 15: 536–550. 78 Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T et al. Regulation of cellular metabolism by protein lysine acetylation. Science 2010; 327: 1000–1004. 79 Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J et al. Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 2006; 23: 607–618. 80 Chang HC, Guarente L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol Metab 2014; 25: 138–145. 81 Scholz C, Weinert BT, Wagner SA, Beli P, Miyake Y, Qi J et al. Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nat Biotechnol 2015; 33: 415–423. 82 Van den Bossche J, Neele AE, Hoeksema MA, de Heij F, Boshuizen MC, van der Velden S et al. Inhibiting epigenetic enzymes to improve atherogenic macrophage functions. Biochem Biophys Res Commun 2014; 455: 396–402. 83 Li T, Liu M, Feng X, Wang Z, Das I, Xu Y et al. Glyceraldehyde-3-phosphate dehydrogenase is activated by lysine 254 acetylation in response to glucose signal. J Biol Chem 2014; 289: 3775–3785. 84 Ventura M, Mateo F, Serratosa J, Salaet I, Carujo S, Bachs O et al. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase is regulated by acetylation. Int J Biochem Cell Biol 2010; 42: 1672–1680. 85 Hallows WC, Yu W, Denu JM. Regulation of glycolytic enzyme phosphoglycerate mutase-1 by Sirt1 protein-mediated deacetylation. J Biol Chem 2012; 287: 3850–3858.

Clinical & Translational Immunology

86 Shan C, Elf S, Ji Q, Kang HB, Zhou L, Hitosugi T et al. Lysine acetylation activates 6-phosphogluconate dehydrogenase to promote tumor growth. Mol Cell 2014; 55: 552–565. 87 Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1: 287–299. 88 Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL. Clinical toxicities of histone deacetylase inhibitorsPharmaceuticals (Basel) 2010; 3: 2751–2767. 89 Vojinovic J, Damjanov N, D'Urzo C, Furlan A, Susic G, Pasic S et al. Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2011; 63: 1452–1458. 90 Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog 2014; 10: e1004473. 91 Ke R, Lewin SR, Elliott JH, Perelson AS. Modeling the effects of vorinostat in vivo reveals both transient and delayed HIV transcriptional activation and minimal killing of latently infected cells. PLoS Pathog 2015; 11: e1005237. 92 Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon AM et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol 2011; 29: 255–265. 93 Fischle W, Dequiedt F, Hendzel M, Guenther M, Lazar M, Voelter W et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 2002; 9: 45–57. 94 Lahm A, Paolini C, Pallaoro M, Nardi MC, Jones P, Neddermann P et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci USA 2007; 104: 17335–17340. 95 Lobera M, Madauss K, Pohlhaus D, Wright Q, Trocha M, Schmidt D et al. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol 2013; 9: 319–325. 96 Jain NK, Mishra V, Mehra NK. Targeted drug delivery to macrophages. Expert Opin Drug Deliv 2013; 10: 353–367. 97 Xia W, Hilgenbrink AR, Matteson EL, Lockwood MB, Cheng JX, Low PS. A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood 2009; 113: 438–446. 98 Lu Y, Wollak KN, Cross VA, Westrick E, Wheeler LW, Stinnette TW et al. Folate receptor-targeted aminopterin therapy is highly effective and specific in experimental models of autoimmune uveitis and autoimmune encephalomyelitis. Clin Immunol 2014; 150: 64–77. 99 Needham LA, Davidson AH, Bawden LJ, Belfield A, Bone EA, Brotherton DH et al. Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs. J Pharmacol Exp Ther 2011; 339: 132–142. 100 Ossenkoppele GJ, Lowenberg B, Zachee P, Vey N, Breems D, Van de Loosdrecht AA et al. A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies. Br J Haematol 2013; 162: 191–201. 101 Kim SJ, Kim JH, Ki CS, Ko YH, Kim JS, Kim WS. Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin. Ann Oncol 2015. 102 Ritchie D, Piekarz RL, Blombery P, Karai LJ, Pittaluga S, Jaffe ES et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica 2009; 94: 1618–1622. 103 Li Y, Zhao T, Liu B, Halaweish I, Mazitschek R, Duan X et al. Inhibition of histone deacetylase 6 improves long-term survival in a lethal septic model. J Trauma Acute Care Surg 2015; 78: 378–385.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http:// creativecommons.org/licenses/by/4.0/